Literature DB >> 32719031

Performance Evaluation of the Novodiag Bacterial GE+ Multiplex PCR Assay.

Charly Roy1, David Robert2, Lucie Bénéjat3,4, Alice Buissonnière3,4, Astrid Ducournau3,4, Francis Mégraud3,4, Emilie Bessède3,4, Delphine Boraud2, Philippe Lehours5,4.   

Abstract

The bacteriological diagnosis of intestinal bacterial infections has historically been based on culture on agar plates. However, culture may lack sensitivity, and some enteropathogens, such as pathovars of Escherichia coli, may escape routine diagnosis. Our goal was to evaluate the analytical performance of the Novodiag Bacterial GE+ kit for the detection of enteropathogenic bacteria in acute community diarrhea. We included 251 stools in this study (198 retrospective and 53 prospective). The analytical performance was calculated using a composite reference standard (CRS) in the absence of a perfect gold standard (lack of sensitivity of culture). The CRS was defined as positive if culture was positive or, in case of a negative culture, if the BD Max extended enteric bacterial panel and/or other real-time PCR (RT-PCR) tests were positive. Of the 251 samples, 200 were positive, and 51 were negative. Overall sensitivities of the Novodiag Bacterial GE+ kit for Campylobacter sp., Salmonella sp., Shigella sp./enteroinvasive E. coli (EIEC), Yersinia enterocolitica, enterohemorrhagic E. coli (EHEC), and enterotoxigenic E. coli (ETEC) ranged from 98.98 to 100%, specificities ranged from 98.08 to 100%, positive predictive values (PPVs) ranged from 88.24 to 100%, and negative predictive values (NVPs) ranged from 99.36 to 100%. The analytical performance of the Novodiag Bacterial GE+ kit is excellent. It can be used as a routine tool in the rapid diagnosis of bacterial gastroenteritis. Despite the eNAT tube dilution of the primary sample, the detection of Salmonella sp. and EHEC was perfect. The kit has the advantage of only detecting pathogenic Y. enterocolitica Its performance for Campylobacter is very satisfactory.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Novodiag Bacterial GE+; analytical performance; digestive infections; syndromic panel based

Mesh:

Year:  2020        PMID: 32719031      PMCID: PMC7512166          DOI: 10.1128/JCM.01033-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Genomic epidemiology of the Escherichia coli O104:H4 outbreaks in Europe, 2011.

Authors:  Yonatan H Grad; Marc Lipsitch; Michael Feldgarden; Harindra M Arachchi; Gustavo C Cerqueira; Michael Fitzgerald; Paul Godfrey; Brian J Haas; Cheryl I Murphy; Carsten Russ; Sean Sykes; Bruce J Walker; Jennifer R Wortman; Sarah Young; Qiandong Zeng; Amr Abouelleil; James Bochicchio; Sara Chauvin; Timothy Desmet; Sharvari Gujja; Caryn McCowan; Anna Montmayeur; Scott Steelman; Jakob Frimodt-Møller; Andreas M Petersen; Carsten Struve; Karen A Krogfelt; Edouard Bingen; François-Xavier Weill; Eric S Lander; Chad Nusbaum; Bruce W Birren; Deborah T Hung; William P Hanage
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  Performance of the Verigene® enteric pathogens test, Biofire FilmArray™ gastrointestinal panel and Luminex xTAG® gastrointestinal pathogen panel for detection of common enteric pathogens.

Authors:  Richard S P Huang; Coreen L Johnson; Lauryn Pritchard; Richard Hepler; Trang T Ton; James J Dunn
Journal:  Diagn Microbiol Infect Dis       Date:  2016-09-22       Impact factor: 2.803

3.  Multicenter evaluation of the BD max enteric bacterial panel PCR assay for rapid detection of Salmonella spp., Shigella spp., Campylobacter spp. (C. jejuni and C. coli), and Shiga toxin 1 and 2 genes.

Authors:  S M Harrington; B W Buchan; C Doern; R Fader; M J Ferraro; D R Pillai; J Rychert; L Doyle; A Lainesse; T Karchmer; J E Mortensen
Journal:  J Clin Microbiol       Date:  2015-03-04       Impact factor: 5.948

4.  Clinical interpretation of enteric molecular diagnostic tests.

Authors:  G A M Tarr; P I Tarr; S B Freedman
Journal:  Clin Microbiol Infect       Date:  2019-09-03       Impact factor: 8.067

5.  A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients.

Authors:  Simon D Goldenberg; Mariana Bacelar; Peter Brazier; Karen Bisnauthsing; Jonathan D Edgeworth
Journal:  J Infect       Date:  2014-11-29       Impact factor: 6.072

6.  Evaluation of CHROMagar STEC and STEC O104 chromogenic agar media for detection of Shiga Toxin-producing Escherichia coli in stool specimens.

Authors:  Malika Gouali; Corinne Ruckly; Isabelle Carle; Monique Lejay-Collin; François-Xavier Weill
Journal:  J Clin Microbiol       Date:  2013-01-02       Impact factor: 5.948

7.  2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Authors:  Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

8.  Foodborne illness acquired in the United States--unspecified agents.

Authors:  Elaine Scallan; Patricia M Griffin; Frederick J Angulo; Robert V Tauxe; Robert M Hoekstra
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

9.  Clinical Yield of a Molecular Diagnostic Panel for Enteric Pathogens in Adult Outpatients With Diarrhea and Validation of Guidelines-Based Criteria for Testing.

Authors:  Stephen D Clark; Michael Sidlak; Amy J Mathers; Melinda Poulter; James A Platts-Mills
Journal:  Open Forum Infect Dis       Date:  2019-04-16       Impact factor: 3.835

10.  How to Interpret a Positive Campylobacter PCR Result Using the BD MAXTM System in the Absence of Positive Culture?

Authors:  Thomas Gueudet; Marie Carole Paolini; Alice Buissonnière; Anne Trens; Jean Marc Rousée; Matthieu Lefranc; Lucie Bénéjat; Astrid Ducournau; Francis Mégraud; Emilie Bessède; Philippe Lehours
Journal:  J Clin Med       Date:  2019-12-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.